NCT05803564招募中不适用
Clinical Application of a New Technique of Thoracoabdominal Aortic Stent System for Endovascular Treatment of Thoracoabdominal Aortic Dissecting Aneurysm.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- The Incidence of Major Adverse Events (MAE) Within 30 Days Postoperative
研究概览
简要总结
A First in man study to evaluate the safety and efficacy of thoracoabdominal aortic stent system for endovascular treatment of thoracoabdominal aortic dissecting aneurysm.
详细描述
The study is mainly for patients with thoraco-abdominal aortic dissecting aneurysm, and all subjects who passed the screening and signed the informed consent will be enrolled. Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system. Patients will be followed up at discharge, 1 month, 6 months, 12 months after the implantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged greater than 18 years old and less than 80 years old;
- •Patients diagnosed with thoraco-abdominal aortic dissecting aneurysm and at least one of the following conditions should be met:
- •a)Maximum aneurysm diameter >50 mm; b）Increase in diameter by more than 5 mm in recent 6 months c）Symptoms such as abdominal pain and back pain associated with thoracic and abdominal aortic dissecting aneurysm were identified.
- •d）Poor morphology of thoracic and abdominal aortic dissecting aneurysm; e）Aortic dissection tears to iliac artery resulting in common iliac artery dissection tumor diameter >40 mm;
- •Anatomic criteria
- •a)The diameter of the proximal anchoring area (aorta or implanted graft) ranged from 17~36 mm to ≥25 mm in length; b）Distal anchoring area (aorta or implanted graft): If distal anchoring area is in iliac artery, anchoring area diameter range 7~25 mm, length ≥15 mm; If the distal anchoring area is in the abdominal aorta, the anchoring area has a diameter of 12~36 mm and a length of ≥20 mm; c）There is a normal anchoring area at the distal end of the visceral branch vessel. The diameter range of the anchoring area is 6~13 mm and the length is ≥15 mm.
- •d）Normal anchoring zone at distal renal artery, anchoring zone diameter 4.5~9 mm, length ≥15 mm; e）Suitable iliac, femoral, and upper limb arterial access.
- •Patients who understand the purpose of the trial, volunteer to participate and sign the informed consent form, and are willing to complete follow-up as required by the protocol;
排除标准
- •Patients with severe hematoma in aortic wall in proximal anchoring area of stent
- •Patients requiring simultaneous coverage and embolization of bilateral internal iliac arteries;
- •Patients with a history of acute coronary syndrome within 6 months; Acute coronary syndromes are cardiac acute ischemic syndromes resulting from rupture of an unstable atherosclerotic plaque in the coronary artery or erosion secondary to the formation of new blood 4 thrombus, including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina.
- •Patients with a transient ischemic attack (TIA) or ischemic/hemorrhagic stroke within 3 months;
- •Patients with preoperative hepatic and renal dysfunction [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the normal upper limit; Serum creatinine (Cr) >150u mol/L];
- •Patients with severe pulmonary insufficiency who cannot tolerate general anesthesia;
- •Patients with severe coagulopathy;
- •Patients with a history of hypersensitivity to contrast agents, anticoagulants, antiplatelet agents, stent delivery devices (i.e., nitinol, polyester, PTFE, nylon polymer materials);
- •Patients with connective tissue diseases such as systemic lupus erythematosus, Marfan syndrome, Egyptian syndrome, or Behcet's disease;
- •Patients with arteritis;
- •Patients with significant organ dysfunction or other serious disease;
- •Women with planned pregnancy, pregnancy stage , or lactation;
- •The patient participated in another clinical trial and was not out or withdrawn within the first 3 months of the screening period of this trial.
- •Patients with a life expectancy of not more than 1 year;
- •Patients judged by the investigator to be unsuitable for endovascular treatment;
结局指标
主要结局
The Incidence of Major Adverse Events (MAE) Within 30 Days Postoperative
时间窗: within 30 days postoperative
Major Adverse events (MAE) are defined as death related to thoracic and abdominal aortic dissecting aneurysms, stroke, permanent paraplegia, kidney failure, intestinal necrosis, myocardial infarction, respiratory failure, and liver failure.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Guo's Visceral Arteries Reconstruction: First in Man StudyThoracoabdominal Aortic AneurysmPararenal Aortic AneurysmNCT04731636Lifetech Scientific (Shenzhen) Co., Ltd.15
已完成
不适用
French Assessment of the Relay Plus and Relay NBS Plus Thoracic Stent-GraftPathology of the Thoracic AortaAneurysm ThoracicPseudo-aneurysm, ThoracicDissection of Thoracic AortaIntramural Haematoma of Thoracic AortaPenetrating Ulcer of Aorta (Disorder)Rupture of the IsthmusNCT05030740Vascutek Ltd.170
招募中
不适用
Thoracoabdominal Artery Stent Graft System Exploratory StudyThoracoabdominal Aortic AneurysmsNCT06710938Lifetech Scientific (Shenzhen) Co., Ltd.11
Unknown
1 期
ENTRUST - TAArget® Thoracic Stent Graft Clinical TrialThoracic Aortic AneurysmNCT01033214Duke Vascular, Inc.30
已完成
3 期
To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic DiseaseAneurysm, DissectingAortic Aneurysm, ThoracicNCT00757003Stanford University100